ABUS: the cashflow

MyFinsight

For the quarter ending 2025-09-30, ABUS had -$15,004K decrease in cash & cash equivalents over the period. -$5,817K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net income (loss)	-7,742	-22,003
Depreciation	11	341
Loss on impairment of leasehold improvements and lab equipment	0	2,811
Stock-based compensation expense	1,263	4,428
Change in fair value of contingent consideration	268	559
Non-cash royalty revenue	249	974
Non-cash interest expense	23	55
Net accretion and amortization of investments in marketable securities	541	1,386
Accounts receivable	-120	-1,384
Prepaid expenses and other assets	-1,040	640
Accounts payable and accrued liabilities	145	-3,056
Change in deferred license revenue	0	-10,434
Other liabilities	-155	-225
Net cash used in operating activities	-5,817	-29,140
Purchase of investments in marketable securities	51,300	63,214
Proceeds from sale of property and equipment	0	9
Disposition of investments in marketable securities	41,281	90,165
Acquisition of property and equipment	0	0
Net cash provided by investing activities	-10,019	26,960
Issuance of common shares pursuant to the open market sale agreement	0	0
Issuance of common shares pursuant to exercise of stock options	794	3,106
Issuance of common shares pursuant to espp	50	131
Net cash provided by financing activities	844	3,237
Effect of foreign exchange rate changes on cash and cash equivalents	-12	25
(decrease) / increase in cash and cash equivalents	-15,004	1,082
Cash and cash equivalents at beginning of period	36,330	-
Cash and cash equivalents at end of period	22,408	-

Unit: Thousand (K) dollars